Advertisement

Topics

Eiger Expands License Agreement with Merck for Investigational Lonafarnib for Treatment of Rare and Fatal Genetic Disease

11:57 EDT 17 May 2018 | Speciality Pharma Journal

PALO ALTO, Calif., May 16, 2018 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has expanded its licensing agreement with Merck, known as MSD outside the United States and Canada, to include rights to develop the investigational farnesyltransferase inhibitor lonafarnib …

Original Article: Eiger Expands License Agreement with Merck for Investigational Lonafarnib for Treatment of Rare and Fatal Genetic Disease

NEXT ARTICLE

More From BioPortfolio on "Eiger Expands License Agreement with Merck for Investigational Lonafarnib for Treatment of Rare and Fatal Genetic Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...